Dissolution of the fibrin blood clot is regulated in large part by plasminogen activator inhibitor-1 (PAI-1). Elevated levels of plasma PAI-1 may be an important risk factor for atherosclerotic vascular disease and are associated with premature myocardial infarction. The role of the endogenous plasminogen activation system in limiting thrombus formation following atherosclerotic plaque disruption is unknown. This study found that genetic deficiency for PAI-1, the primary physiologic regulator of tissue-type plasminogen activator (tPA), prolonged the time to occlusive thrombosis following photochemical injury to carotid atherosclerotic plaque in apolipoprotein E-deficient (apoE−/−) mice. However, anatomic analysis revealed a striking difference in the extent of atherosclerosis at the carotid artery bifurcation between apoE−/− mice and mice doubly deficient for apoE and PAI-1 (PAI-1−/−/apoE−/−). Consistent with a previous report, PAI-1+/+/apoE−/−and PAI-1−/−/apoE−/− mice developed similar atherosclerosis in the aortic arch. The marked protection from atherosclerosis progression at the carotid bifurcation conferred by PAI-1 deficiency suggests a critical role for PAI-1 in the pathogenesis of atherosclerosis at sites of turbulent flow, potentially through the inhibition of fibrin clearance. Consistent with this hypothesis, intense fibrinogen/fibrin staining was observed in atherosclerotic lesions at the carotid bifurcation compared to the aortic arch. These observations identify significant differences in the pathogenesis of atherosclerosis at varying sites in the vascular tree and suggest a previously unappreciated role for the plasminogen activation system in atherosclerosis progression at sites of turbulent flow.

Human atherosclerosis is a complex, multifactorial disease involving repetitive vascular injury, lipid accumulation, platelet and fibrin deposition, and cellular migration and proliferation.1 Complications of atherosclerosis are the leading cause of death in industrialized societies. Disruption of atherosclerotic plaques leading to occlusive thrombosis is the immediate cause of most acute coronary syndromes.1Subocclusive thrombosis may also occur, contributing to plaque growth, as evidenced by the presence of extensive fibrin deposition in most complex atherosclerotic lesions.2,3 Plasma fibrinogen levels in humans have been shown to be an independent risk factor for myocardial infarction.4 Elevated fibrinogen may also affect the process of atherogenesis by leading to enhanced thrombosis and fibrin deposition within developing atherosclerotic lesions.2,3 Intravascular clearance of fibrin is predominantly mediated by plasmin, which is formed from plasminogen by the action of the plasminogen activators (PAs), tissue-type plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA). Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of the PAs,5 and elevated levels of PAI-1 have been identified as a risk factor for myocardial infarction in humans.6 

With continued advances in transgenic technology, the mouse has become a uniquely powerful model in which to study the complex genetic factors contributing to atherosclerosis progression. Targeted deletion of genes involved in lipoprotein metabolism have produced mice that develop atherosclerosis similar to that observed in humans.7-9Deficiency of apolipoprotein E (apoE) leads to an especially severe form of atherosclerosis that is accelerated with high-fat chow.7 Within the vascular tree of these mice, bifurcation sites are predisposed to the development of atherosclerosis10 similar to the pattern observed in humans.11 

Transgenic mouse studies examining the role of fibrinogen and fibrin clearance in atherosclerosis have yielded conflicting results. Although mice doubly deficient for apoE and plasminogen develop accelerated atherosclerosis,12 deficiency of fibrinogen appears to have no significant effect on atherosclerotic lesion growth in the aortic arch of apoE−/− mice.13 While examining the effect of PAI-1 on the susceptibility of carotid plaques in apoE−/− mice to form occlusive thrombosis, we observed marked protection from carotid atherosclerosis in apoE−/−mice deficient in PAI-1. These observations identify significant differences in the pathogenesis of atherosclerosis at varying sites in the vascular tree and suggest a previously unappreciated role for the plasminogen activation system in atherosclerosis progression at sites of turbulent flow.

Mice

The PAI-1–deficient mice (a gift of P. Carmeliet and D. Collen) were generated by homologous recombination as previously described.14 ApoE−/− mice8 were purchased from the Jackson Laboratory (Bar Harbor, ME). PAI-1−/−mice were back-crossed to C57BL/6J (for 5 generations) and apoE−/− mice were back-crossed to C57BL/6J mice (for 6 generations) before cross-breeding. Double heterozygous (PAI-1+/−/apoE+/−) mice were intercrossed to produce the double PAI-1−/−/apoE−/− mice, which were identified by polymerase chain reaction analysis of tail DNA specimens. Primer sequences for identification of PAI-1 and apoE wild-type and null alleles were as previously described.15 Mice were maintained on standard chow or Teklad Western diet (TD 88137). Because of unexpected differences in the extent of carotid atherosclerosis (see “Results”) between PAI-1−/−/apoE−/− and PAI-1+/+/apoE−/− mice on a normal diet that contradicted our previous studies, an additional group of mice that had been maintained on high-fat (Western) chow were also analyzed. This group of mice on the Western chow (gift of W. Fay) had also received a ferric chloride-induced injury to one carotid artery as part of a previous study. These mice were of the same C57BL/6J genetic background as the older mice. Only the aortic arch and uninjured carotid artery from these animals were analyzed. All animal care and experimental procedures complied with the “Principles of Laboratory and Animal Care” established by the National Society for Medical Research and were approved by the University of Michigan Committee on Use and Care of Animals.

Carotid arterial thrombosis protocol

Thirty-week-old male apoE−/− mice along with 30-week-old combined PAI-1−/−/apoE−/− mice were subjected to photochemical injury of the right carotid artery as previously described.16 Flow in the vessel was monitored for 150 minutes or until cessation of flow occurred, at which time the experiment was terminated.

Analysis of atherosclerotic lesions

At 18, 30, or 52 weeks of age, mice were perfusion fixed with zinc formalin under intraperitoneal pentobarbital anesthesia (100 mg/kg). The common carotid artery including the bifurcation of the internal and external carotid was dissected and embedded in paraffin. Serial sections at 50-μm intervals were inspected moving from the common carotid artery into the bifurcation. At the onset of the bifurcation, 10 sections were stained with hematoxylin and eosin and subjected to quantitative morphometric analysis as previously described.15 For quantitation of surface area occupied by atherosclerosis, the aorta and its major branches were stained with oil red O as previously described7 and then subjected to quantitative morphometry. The operator was aware of the mouse genotype during quantitation. Staining for fibrinogen/fibrin was performed with a polyclonal goat antimouse antibody15 as previously described.

Statistical analysis

The statistical significance of differences of time to occlusion and intimal lesion area between the various groups was determined using the Student 2-tailed t test. A P value of less than .05 was considered significant.

Effect of PAI-1 deficiency on development of occlusive thrombosis following plaque injury

We recently demonstrated that the level of PAI-1 expression significantly modifies the rate of thrombus formation in the mouse carotid artery following photochemical injury.17 We have also shown that this type of injury can be performed to atherosclerotic lesions and that the time to occlusion is decreased in diseased compared to nondiseased arteries,16 suggesting that murine plaque is highly thrombogenic, similar to the human lesion.18 To examine the contribution of PAI-1 in this model for the acute thrombosis associated with plaque disruption, 30-week-old PAI-1−/−/apoE−/− mice were subjected to photochemical injury at the site of an atherosclerotic lesion just proximal to the carotid bifurcation. The mean time to occlusion in these mice (n = 6) was 65 ± 7 minutes, which is significantly prolonged compared to our previously reported occlusion time of 44 ± 5 minutes in 30-week-old PAI-1+/+/apoE−/− mice (n = 9)16(P < .03).

Effect of PAI-1 deficiency on development of atherosclerosis at the carotid bifurcation and aortic arch

To examine potential anatomic differences in the atherosclerotic lesions at the carotid bifurcation, 52-week-old PAI-1−/−/apoE−/− or PAI-1+/+/apoE−/− male mice, maintained on a normal chow diet, were killed and the aorta with its major branches was dissected free of connective tissue and stained for lipid with Oil Red O.7 Although the extent of atherosclerosis involving the proximal aortic arch appeared similar between PAI-1−/−/apoE−/−and PAI-1+/+/apoE−/− mice, a marked difference in carotid disease was observed (Figure 1A). Total lesion surface area in the aortic arch and the carotid arteries as determined by quantitative morphometry is shown in Figure 1B. Consistent with our previous report,15 the mean lesion area in the aortic arch was not significantly different, although there was a trend toward less disease in the PAI-1−/−/apoE−/− group. However, marked differences in lesion surface area were observed in the carotid distribution. Quantitative analysis of intimal lesion area on histologic cross sections (Figure 1C) confirmed the dramatic protection against atherosclerosis at the carotid bifurcation afforded by PAI-1 deficiency. At 30 weeks, significant intimal thickening is evident in the carotid artery bifurcations of PAI-1+/+/apoE−/− mice maintained on normal chow, whereas little or no disease is observed in PAI-1−/−/apoE−/− mice at the same time point (Figure 1C). A more modest decrease in lesion area at the aortic arch was also observed in PAI-1−/−/apoE−/−mice compared to apoE−/− controls, achieving statistical significance at the 52-week time point.

Fig. 1.

Analysis of atherosclerosis.

(A) Oil red O staining of atherosclerotic lesions in aortic arch and carotid arteries of 52-week-old mice on normal chow. Atherosclerosis of the distal common carotid and carotid bifurcation is markedly diminished in the PAI-1−/−/apoE−/− mice compared to PAI-1+/+/apoE−/− mice, whereas atherosclerosis involving the aortic arch appears similar. Arrows show aortic arch (vertical) and carotid bifurcation (horizontal). (B) Quantitation of aortic and carotid arterial atherosclerosis in 52-week-old PAI-1−/−/apoE−/− mice (n = 8) (■) and PAI-1+/+/apoE−/− mice (n = 6) (▧) on normal chow. *P < .0003, #P > .1. (C) Cross-sectional area of atherosclerotic lesions in 30-week-old PAI-1−/−/apoE−/− (n = 10) and PAI-1+/+/apoE−/− mice (n = 7) maintained on normal chow and in 52-week-old PAI-1−/−/apoE−/− (n = 9) and PAI-1+/+/apoE−/− mice (n = 6) maintained on normal chow. Intima-to-media (I/M) ratio in PAI-1−/−/apoE−/− mice (■) and PAI-1+/+/apoE−/− mice (▧). *P < .01, **P < 2 × 10−8. (D) Quantification of lesion area in 18-week-old PAI-1−/−/apoE−/− mice (n = 5) (■) and PAI-1+/+/apoE−/− mice (n = 5) (▧) on high-fat chow. *P < .05, #P > .2. (E) I/M ratios in PAI-1−/−/apoE−/− mice (n = 5) (■) and PAI-1+/+/apoE−/− mice (n = 5) (▧) on high-fat chow. *P < .05, #P > .1.

Fig. 1.

Analysis of atherosclerosis.

(A) Oil red O staining of atherosclerotic lesions in aortic arch and carotid arteries of 52-week-old mice on normal chow. Atherosclerosis of the distal common carotid and carotid bifurcation is markedly diminished in the PAI-1−/−/apoE−/− mice compared to PAI-1+/+/apoE−/− mice, whereas atherosclerosis involving the aortic arch appears similar. Arrows show aortic arch (vertical) and carotid bifurcation (horizontal). (B) Quantitation of aortic and carotid arterial atherosclerosis in 52-week-old PAI-1−/−/apoE−/− mice (n = 8) (■) and PAI-1+/+/apoE−/− mice (n = 6) (▧) on normal chow. *P < .0003, #P > .1. (C) Cross-sectional area of atherosclerotic lesions in 30-week-old PAI-1−/−/apoE−/− (n = 10) and PAI-1+/+/apoE−/− mice (n = 7) maintained on normal chow and in 52-week-old PAI-1−/−/apoE−/− (n = 9) and PAI-1+/+/apoE−/− mice (n = 6) maintained on normal chow. Intima-to-media (I/M) ratio in PAI-1−/−/apoE−/− mice (■) and PAI-1+/+/apoE−/− mice (▧). *P < .01, **P < 2 × 10−8. (D) Quantification of lesion area in 18-week-old PAI-1−/−/apoE−/− mice (n = 5) (■) and PAI-1+/+/apoE−/− mice (n = 5) (▧) on high-fat chow. *P < .05, #P > .2. (E) I/M ratios in PAI-1−/−/apoE−/− mice (n = 5) (■) and PAI-1+/+/apoE−/− mice (n = 5) (▧) on high-fat chow. *P < .05, #P > .1.

Close modal

The latter data contrast with our previous report15 in which absence or overexpression of PAI-1 produced no significant difference in aortic arch lesion thickness, when examined in both the apoE−/− and LDLR−/− murine atherosclerosis models. The latter studies were performed on a high-fat diet, which is known to accelerate the growth of atherosclerotic lesions and may have overwhelmed the effect of varying PAI-1 expression. To address the potential contribution of diet, we analyzed an additional group of 18-week-old mice (5 mice in each group) fed high-fat chow for 8 weeks (Figure 1D). Similar to the mice on regular chow, PAI-1 deficiency resulted in a marked decrease in lesion surface area at the distal common carotid artery compared to apoE−/− controls (3.2 ± 1.0 versus 0.42 ± 0.2,P < .03) However, consistent with our previous report, no significant differences were observed in the ascending aorta, although there was a trend toward less lesion area in PAI-1−/−/apoE−/− mice (10.5 ± 1.3 versus 7.5 ± 1.8, P = .2). A similar pattern was observed for the intimal lesion thickness (Figure 1E).

Fibrin/fibrinogen immunohistochemistry

No significant differences in lesion composition or morphology were evident among the genetically distinct experimental groups on routine histologic analysis. However, immunohistochemical staining for fibrin/fibrinogen revealed evidence of fibrin/fibrinogen deposition at all sites of lesion formation, considerably more extensive at the distal common carotid artery of PAI-1+/+/apoE−/− mice compared to the ascending aorta (Figure 2). PAI-1−/−/apoE−/− mice would be expected to exhibit less fibrin deposition in plaques compared to PAI-1+/+/apoE−/− mice; however, no major differences were noted between the 2 groups although direct comparisons are difficult due to differences in lesion size.

Fig. 2.

Fibrin/fibrinogen staining of atherosclerotic lesions in 52-week-old apoE−/− mice.

Left panel shows ascending aorta; right panel shows distal common carotid artery. Fibrin/fibrinogen, identified by red staining, is more extensive at the carotid bifurcation than the aortic arch. M indicates media; IEL, internal elastic lamina; P, plaque.

Fig. 2.

Fibrin/fibrinogen staining of atherosclerotic lesions in 52-week-old apoE−/− mice.

Left panel shows ascending aorta; right panel shows distal common carotid artery. Fibrin/fibrinogen, identified by red staining, is more extensive at the carotid bifurcation than the aortic arch. M indicates media; IEL, internal elastic lamina; P, plaque.

Close modal

Plasminogen activator inhibitor-1 is expressed at sites of vascular disease and has been proposed to play an important role in the pathogenesis of human atherosclerosis.19,20 Because PAI-1 is the primary regulator of fibrinolytic activity in vivo,21 deficiency of PAI-1 might be expected to enhance fibrinolysis and attenuate the growth of atherosclerotic plaques. However, PAI-1 also appears to regulate cellular migration via fibrin-independent mechanisms,22,23 with PAI-1 blocking cellular accumulation at sites of extrinsic vascular injury in several rodent models.24,25 Human clinical studies of the association between plasma PAI-1 level and atherosclerotic vascular disease have yielded conflicting results.6,26 A common polymorphism in the PAI-1 promoter resulting in alteredPAI-1 gene expression in vitro has been associated with increased cardiovascular risk in some studies though not confirmed in others.27-30 

Our data suggest that the relative contribution of fibrin deposition and PA activity to the pathogenesis of atherosclerosis may vary considerably at different sites within the vasculature. Taken together with our previous results,15 these findings also suggest that the marked hypercholesterolemia and accelerated atherosclerosis associated with high-fat feeding in apoE−/− mice may obscure subtle contributions from nonlipid factors that are likely to be relevant in human disease, including alterations in hemostatic balance. The lesions that develop in the carotid arteries of PAI-1+/+/apoE−/− mice involve the distal common carotid artery and typically extend across the bifurcation into the internal and external carotids (Figure 1A). Bifurcation sites in humans are similarly predisposed to the development of atherosclerosis11 and unique hemodynamic forces may affect development of lesions at these sites.

Shear stress has been shown to increase the expression of tPA, which may affect fibrin clearance.31,32 Other factors contributing to fibrin turnover have been shown to correlate with the development of atherosclerosis at the carotid bifurcation in humans.33 These observations suggest that delayed fibrin clearance may provide an expanded matrix for accelerated plaque growth. Consistent with this hypothesis, accelerated atherosclerosis has also been reported in apoE−/− mice deficient in plasminogen.12 In contrast, fibrinogen deficiency fails to protect apoE−/− mice from atherosclerosis progression.13 However, the latter results were based on analysis restricted to the proximal aorta, and significant differences at the more distal sites studied in the current report cannot be excluded. The confounding effect of strain modifier genes in these and other previous reports34 could also obscure significant differences in plaque burden. We studied mice on the C57BL/6J background because this strain has become the standard inbred strain for atherosclerosis studies. It is possible that the effect of PAI-1 observed in these studies could vary on different genetic backgrounds. Dansky and coworkers34 have demonstrated marked differences in atherosclerotic burden in apoE−/− mice on the FVB/NJ background compared to the C57BL/6J background. Although the aorta has been the standard site for quantitative analysis of atherosclerosis in genetically modified mice,35 our results suggest that atherosclerosis progression at other sites in the vascular tree may be more relevant to the complex mechanisms underlying the pathogenesis of human coronary atherosclerosis.

Taking all of these results together, we propose that chronic low-grade fibrin deposition following repetitive vascular injury facilitates the growth of atherosclerotic plaques, particularly at sites of altered hemodynamics and turbulent flow. In addition to its direct role as a regulator of acute intravascular thrombosis,17 PAI-1 may also contribute to chronic plaque growth and thrombogenicity through its effect on fibrinolytic balance. These results suggest that pharmacologic inhibition of PAI-1 may be a useful therapeutic strategy, for preventing acute coronary thrombosis in susceptible vessels as well as delaying development of the primary atherosclerotic lesion.

We thank William Fay for providing 18-week-old mice on Western chow and Angela Yang for assistance with fibrin staining.

Supported by National Institutes of Health grants HL-035989 and HL-036195 (D.E.) and HL-57345 (D.G.). D.G. is a Howard Hughes Medical Institute investigator.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Ross
 
R
The pathogenesis of atherosclerosis: a perspective for the 1990s.
Nature.
362
1993
801
809
2
Bini
 
A
Fenoglio
 
JJ
Mesa-Tejada
 
R
Kudryk
 
B
Kaplan
 
KL
Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.
Arteriosclerosis.
9
1989
109
121
3
Schwartz
 
CJ
Valente
 
AJ
Kelley
 
JL
Sprague
 
EA
Edwards
 
EH
Thrombosis and the development of atherosclerosis: Rokitansky revisited.
Semin Thromb Haemost.
14
1988
189
195
4
Wilhelmsen
 
L
Svardsudd
 
K
Korsan-Bengtsen
 
K
Larsson
 
B
Welin
 
L
Tibblin
 
G
Fibrinogen as a risk factor for stroke and myocardial infarction.
N Engl J Med.
311
1984
501
505
5
Loskutoff
 
DJ
A slice of PAI.
J Clin Invest.
92
1993
2563
6
Hamsten
 
A
Wiman
 
B
de Faire
 
U
Blomback
 
M
Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
N Engl J Med.
313
1985
1557
1563
7
Plump
 
AS
Smith
 
JD
Hayek
 
T
et al
Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.
Cell.
71
1992
343
353
8
Zhang
 
SH
Reddick
 
RL
Piedrahita
 
JA
Maeda
 
N
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.
Science.
258
1992
468
471
9
Ishibashi
 
S
Goldstein
 
JL
Brown
 
MS
Herz
 
J
Burns
 
DK
Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice.
J Clin Invest.
93
1994
1885
1893
10
Nakashima
 
Y
Plump
 
AS
Raines
 
EW
Breslow
 
JL
Ross
 
R
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Arterioscler Thromb Vasc Biol.
14
1994
133
140
11
Ding
 
Z
Biggs
 
T
Seed
 
WA
Friedman
 
MH
Influence of the geometry of the left main coronary artery bifurcation on the distribution of sudanophilia in the daughter vessels.
Arterioscler Thromb Vasc Biol.
17
1997
1356
1360
12
Xiao
 
Q
Danton
 
M
Witte
 
DP
et al
Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis.
Proc Natl Acad Sci U S A.
94
1997
10335
10340
13
Xiao
 
Q
Danton
 
MJ
Witte
 
DP
Kowala
 
MC
Valentine
 
MT
Degen
 
JL
Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.
J Clin Invest.
101
1998
1184
1194
14
Carmeliet
 
P
Kieckens
 
L
Schoonjans
 
L
et al
Plasminogen activator inhibitor-1 gene-deficient mice, I. Generation by homologous recombination and characterization.
J Clin Invest.
92
1993
2746
2755
15
Sjoland
 
H
Eitzman
 
DT
Gordon
 
D
Westrick
 
RJ
Nabel
 
EG
Ginsburg
 
D
Atherosclerosis progression in LDL receptor deficient and apolipoprotein E deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.
Arterioscler Thromb Vasc Biol.
20
2000
846
852
16
Eitzman
 
DT
Westrick
 
RJ
Xu
 
Z
Tyson
 
J
Ginsburg
 
D
Hyperlipidemia promotes thrombosis following injury to atherosclerotic vessels in apolipoprotien E deficient mice.
Arterioscler Thromb Vasc Biol.
20
2000
1831
1834
17
Eitzman
 
DT
Westrick
 
RJ
Nabel
 
EG
Ginsburg
 
D
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.
Blood.
95
2000
577
580
18
DeWood
 
MA
Stifter
 
WF
Simpson
 
CS
et al
Coronary arteriographic findings soon after non-Q-wave myocardial infarction.
N Engl J Med.
315
1986
417
423
19
Olofsson
 
BO
Dahlen
 
G
Nilsson
 
TK
Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.
Eur Heart J.
10
1989
77
82
20
Cortellaro
 
M
Cofrancesco
 
E
Boschetti
 
C
et al
Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group.
Arterioscler Thromb Vasc Biol.
13
1993
1412
1417
21
Loskutoff
 
DJ
Sawdey
 
M
Mimuro
 
J
Type 1 plasminogen activator inhibitor.
Prog Hemost Thromb.
9
1989
87
115
22
Stefansson
 
S
Lawrence
 
DA
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Nature.
383
1996
441
443
23
Bajou
 
K
Noel
 
A
Gerard
 
RD
et al
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Nat Med.
4
1998
923
928
24
Carmeliet
 
P
Moons
 
L
Lijnen
 
R
et al
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation.
Circulation.
96
1997
3180
3191
25
Hasenstab
 
D
Lea
 
H
Clowes
 
A
Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening.
Arterioscler Thromb Vasc Biol.
20
2000
853
859
26
Thompson
 
SG
Kienast
 
J
Pyke
 
SD
Haverkate
 
F
van de Loo
 
JC
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
N Engl J Med.
332
1995
635
641
27
Doggen
 
CJ
Bertina
 
RM
Cats
 
VM
Reitsma
 
PH
Rosendaal
 
FR
The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction.
Thromb Haemost.
82
1999
115
120
28
Gardemann
 
A
Lohre
 
J
Katz
 
N
Tillmanns
 
H
Hehrlein
 
FW
Haberbosch
 
W
The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease.
Thromb Haemost.
82
1999
1121
1126
29
Ye
 
S
Green
 
FR
Scarabin
 
PY
et al
The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
Thromb Haemost.
74
1995
837
841
30
Eriksson
 
P
Kallin
 
B
van 't
 
H
Bavenholm
 
P
Hamsten
 
A
Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.
Proc Natl Acad Sci U S A.
92
1995
1851
1855
31
Papadaki
 
M
Ruef
 
J
Nguyen
 
KT
et al
Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells.
Circ Res.
83
1998
1027
1034
32
Diamond
 
SL
Eskin
 
SG
McIntire
 
LV
Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells.
Science.
243
1989
1483
1485
33
Rankinen
 
T
Vaisanen
 
S
Mercuri
 
M
Rauramaa
 
R
Apolipoprotein(a), fibrinopeptide A and carotid atherosclerosis in middle-aged men [see comments].
Thromb Haemost.
72
1994
563
566
34
Dansky
 
HM
Charlton
 
SA
Sikes
 
JL
et al
Genetic background determines the extent of atherosclerosis in ApoE-deficient mice.
Arterioscler Thromb Vasc Biol.
19
1999
1960
1968
35
Paigen
 
B
Morrow
 
A
Holmes
 
PA
Mitchell
 
D
Williams
 
RA
Quantitative assessment of atherosclerotic lesions in mice.
Atherosclerosis.
68
1987
231
240

Author notes

Daniel T. Eitzman, University of Michigan Medical Center, MSRB III Room 7301, 1150 Medical Center Drive, Ann Arbor, MI 48109-0644; e-mail: deitzman@umich.edu.

Sign in via your Institution